Archives antérieures

Accueil > LYSA > Consulter nos publications et présentations lors de congrès > Publications scientifiques LYSA > Archives antérieures
Lysa 2020_LYSA_Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group
Yannick Le Bris, Florence Magrangeas, Anne Moreau, David Chiron, Catherine Guérin-Charbonnel, Olivier Theisen, Olivier Pichon, Danielle Canioni, Barbara Burroni, Hervé Maisonneuve, Catherine Thieblemont, Lucie Oberic, Emmanuel Gyan, Catherine Pellat-Deceunynck, Olivier Hermine, Marie-Hélène Delfau-Larue, Benoît Tessoulin, Marie-Christine Béné, Stéphane Minvielle, Steven Le Gouill
Hematol Oncol . 2020 Oct;38(4):446-455. doi: 10.1002/hon.2750. En savoir plus
Lysa 2020_LYSA_Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T 3 phase IB trial of the LYSA
Benoît Tessoulin, Kamal Bouabdallah, Barbara Burroni, Thierry Lamy, Remy Gressin, Guillaume Cartron, Catherine Thieblemont, Clémentine Sarkozy, Corinne Haioun, Olivier Casasnovas, Clementine Joubert, Emmanuel Gyan, Olivier Hermine, Steven Le Gouill
Ann Hematol . 2020 Aug;99(8):1771-1778. doi: 10.1007/s00277-020-04159-3. En savoir plus
Lysa 2020_LYSA_Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, Rene-Olivier Casasnovas, François Lemonnier, Gian Matteo Pica, Roch Houot, Loic Ysebaert, Hervé Tilly, Jean-Claude Eisenmann, Steven Le Gouill, Vincent Ribrag, Pascal Godmer, Sylvie Glaisner, Guillaume Cartron, Luc Xerri, Gilles André Salles, Thierry Fest, Franck Morschhauser
Blood Adv . 2020 Aug 11;4(14):3217-3223. doi: 10.1182/bloodadvances.2020001955. En savoir plus
Lysa 2020_LYSA_Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network
Paul Blanc-Durand, Simon Jégou, Salim Kanoun, Alina Berriolo-Riedinger, Caroline Bodet-Milin, Françoise Kraeber-Bodéré, Thomas Carlier, Steven Le Gouill, René-Olivier Casasnovas, Michel Meignan, Emmanuel Itti
Eur J Nucl Med Mol Imaging . 2020 Oct 24. doi: 10.1007/s00259-020-05080-7 En savoir plus
Lysa 2020_LYSA_Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
Steven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, Victoria Cacheux, Violaine Safar, Barbara Burroni, Stéphanie Guidez, Thomas Gastinne, Danielle Canioni, Catherine Thieblemont, Hervé Maisonneuve, Caroline Bodet-Milin, Roch Houot, Lucie Oberic, Krimo Bouabdallah, Charles Bescond, Ghandi Damaj, Arnaud Jaccard, Nicolas Daguindau, Anne Moreau, Hervé Tilly, Vincent Ribrag, Marie-Hélène Delfau-Larue, Olivier Hermine, Elizabeth Macintyre
https://doi.org/10.1016/S2352-3026(20)30291-X En savoir plus
Lysa 2020_LYSA_Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pamela McKay, Tycel Phillips, De Sarit Assouline, Connie LeeBatlevi, Phillip Campbell, Vincent Ribrag, Gandhi Laurent Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Gilles Salles
https://doi.org/10.1016/S1470-2045(20)30441-1 En savoir plus
Lysa 2020_LYSA_Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA
Steven Le Gouill, Herve Ghesquieres, Lucie Obéric, Franck Morschhauser, Herve Tilly, Vincent Ribrag, Thierry Lamy, Catherine Thieblemont, Herve Gerard Maisonneuve, Remy Gressin, Krimo Bouabdallah, Corinne Haioun, Gandhi Damaj, Luc-Matthieu Fornecker, Reda Bouabdallah, Pierre Feugier, David Sibon, Guillaume Cartron, Christophe Bonnet, Marc André, Loic Chartier, Philippe Ruminy, F Kraeber-Bodere, C Bodet-Milin, Alina Berriolo-Riedinger, Josette Briere, Jean-Philippe Jais, Thierry Molina, Emmanuel Itti, Olivier Casasnovas
Blood. 2020 Nov 19;blood.2020008750. doi: 10.1182/blood.2020008750 En savoir plus
Lysa 2020_LYSA_Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
A S Cottereau, M Meignan, C Nioche, N Capobianco, J Clerc, L Chartier, L Vercellino, O Casasnovas, C Thieblemont, I Buvat
Ann Oncol . 2020 Dec 2;S0923-7534(20)43174-6. doi: 10.1016/j.annonc.2020.11.019. En savoir plus
Lysa 2020_LYSA_Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino, Roberta Di Blasi, Salim Kanoun, Benoit Tessoulin, Cedric Rossi, Maud D'Aveni-Piney, Lucie Obéric, Caroline Bodet-Milin, Pierre Bories, Pierre Olivier, Ingrid Lafon, Alina Berriolo-Riedinger, Eugenio Galli, Sophie Bernard, Marie-Thérèse Rubio, Celine Bossard, Veronique Meignin, Pascal Merlet, Pierre Feugier, Steven Le Gouill, Loic Ysebaert, Olivier Casasnovas, Michel Meignan, Sylvie Chevret, Catherine Thieblemont
Blood Adv . 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. En savoir plus
Calym 2017_RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Viziteu E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzones C, Tiers L, Bruyer A, Vincent L, Grandmougin C, Seckinger A, Goldschmidt H, Constantinou A, Pasero P, Hose D and Moreaux J
2017. Jun 2;45(10):5639-5652. En savoir plus
Calym 2017_Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.
Kassambara A, Jourdan M, Bruyer A, Robert N, Pantesco V, Elemento O, Klein B, Moreaux J.
2017. Jun 2;45(10):5639-5652. En savoir plus
Calym 2018_SAMHD1 acts at stalled replication forks to prevent induction of interferon.
Coquel F#, Silva M-J#, Técher H#, Zadorozhny K, Sushma S, Nieminuszczy J, Mettling C, Dardillac E, Barthe A, Schmitz AL, Promonet A, Cribier A, Sarrazin A, Niedzwiedz W, Lopez B, Costanzo V, Krejci L, Chabes A, Benkirane M, Lin YL* and Pasero P*
Nature, 557, 57-61. En savoir plus
Calym 2019_EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation.
Herviou L, Jourdan M, Martinez AM, Cavalli G, Moreaux J.
Leukemia. 2019. Aug;33(8):2047-2060. En savoir plus
2019_CSF1R and BTK inhibitions as novel strategies to disrupt the dialogue between mantle cell lymphoma and macrophages
Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve A, Moreau P, Touzeau C, Amiot M, Pellat-Deceunynck C, Le Gouill S, Chiron D.
Leukemia. 2019 33(10):2442-2453. En savoir plus
Calym 2018_Whole Exon Sequencing of Human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maiga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C.
J Hematol Oncol. 2018, 11:137 En savoir plus
Calym 2018_p53 regulates CD46 expression and Measles virus infection in myeloma cells.
Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, -, Le Bris Y, Vabret A, Bellanger C, --- Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C
Blood Adv. 2018; 2:3492-3505. En savoir plus
Lysa 2018_BH3 mimetic toolkit guides the respective use of BCL2 and MCL1 BH3 mimetics in myeloma treatment.
Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez M, Le Gouill S, Touzeau C, Moreau P, Pellat-Deceunynck C, Amiot M.
Blood 2018;132: 2656-2669 En savoir plus
Calym 2016_Microenvironment-dependent proliferation and mitochondrial priming loss in mantle cell lymphoma is overcome by anti-CD20.
Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, Moreau A, Esbelin J, Trichet V, Chen-Kiang S, Moreau P, Touzeau C, Le Gouill S, Amiot M, Pellat-Deceunynck C.
Blood. 2016; 128:2808-2818 En savoir plus
Lysa 2020_LYSA_Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma
Jaffe ES, Ashar BS, Clemens MW, Feldman AL, Gaulard P, Miranda RN, Sohani AR, Stenzel T, Yoon SW
J Clin Oncol. 2020 Apr 1;38(10):1102-1111. doi: 10.1200/JCO.19.02778. En savoir plus
Lysa 2019_LYSA_PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M
https://www.ncbi.nlm.nih.gov/pubmed/30658935
Lysarc 2020_LYSA_The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL
Sarit Assouline, Shen Li, Christian Gisselbrecht, Patrick Fogarty, Annette Hay, Eric van den Neste, Lois E. Shepherd, Norbert Schmitz, Tara Baetz, Armand Keating, Sue Robinson, Matthew Seftel, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, and Michael Crump
https://pubmed.ncbi.nlm.nih.gov/
Lysa 2020_LYSA_Combining Gene Expression Profiling and Machine Learning to Diagnose B-cell non-Hodgkin Lymphoma
Victor Bobée, Fanny Drieux, Vinciane Marchand, Vincent Sater, Liana Veresezan, Jean-Michel Picquenot, Pierre-Julien Viailly, Marie-Delphine Lanic, Mathieu Viennot, Elodie Bohers, Lucie Oberic, Christiane Copie-Bergman, Thierry Jo Molina, Philippe Gaulard, Corinne Haioun, Gilles Salles, Hervé Tilly, Fabrice Jardin, Philippe Ruminy
https://www.ncbi.nlm.nih.gov/pubmed/32444689
Lysa 2020_LYSA_Lenalidomide Maintenance for Diffuse Large B-cell Lymphoma Patients Responding to R-CHOP: Quality of Life, Dosing, and Safety Results From the Randomised Controlled REMARC Study
Catherine Thieblemont, Susannah Howlett, René-Olivier Casasnovas, Nicolas Mounier, Aurore Perrot, Franck Morschhauser, Christophe Fruchart, Nicolas Daguindau, Koen van Eygen, Lucie Obéric, Reda Bouabdallah, Gian Matteo Pica, Emmanuelle Nicolas-Virezelier, Julie Abraham, Olivier Fitoussi, Sylvia Snauwaert, Jean-Claude Eisenmann, Pauline Lionne-Huyghe, Dominique Bron, Sabine Tricot, Dries Deeren, Hugo Gonzalez, Régis Costello, Katell Le Du, Maria Gomes da Silva, Sebastian Grosicki, Judith Trotman, John Catalano, Dolores Caballero, Richard Greil, Amos M Cohen, Philippe Gaulard, Louise Roulin, Kenichi Takeshita, Marie-Laure Casadebaig, Hervé Tilly, Bertrand Coiffier
Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. En savoir plus
Lysa 2020_LYSA_High Total Metabolic Tumor Volume at Baseline Predicts Survival Independent of Response to Therapy
Laetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, Hervé Tilly, Pierre Feugier, Loic Chartier, Christophe Fruchart, Louise Roulin, Lucie Oberic, Gian Matteo Pica, Vincent Ribrag, Julie Abraham, Marc Simon, Hugo Gonzalez, Reda Bouabdallah, Olivier Fitoussi, Catherine Sebban, Armando López-Guillermo, Laurence Sanhes, Franck Morschhauser, Judith Trotman, Bernadette Corront, Bachra Choufi, Sylvia Snauwaert, Pascal Godmer, Josette Briere, Gilles Salles, Philippe Gaulard, Michel Meignan, Catherine Thieblemont
Blood 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526 En savoir plus
Lysa 2020_LYSA_Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R, Devillers A, Lamy T, Thieblemont C, Hermine O, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C
Haematologica. 2020 Jan;105(1):e33-e36. doi: 10.3324/haematol.2019.223016 En savoir plus
Lysa 2020_LYSA_REALYSA : une cohorte française multicentrique en vie réelle de patients adultes atteints d’un lymphome
H. Ghesquières, A. Bernier, F. Cherblanc, A. Belot, S. Le Guyader-Peyrou, A. Monnereau
Correspondances en Onco-Hématologie N° 4 / sept. 2020 En savoir plus
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.
Blood 2018 Jan 11;131(2):174-181
Through the Glass Ceiling.
Tilly H, Salles G, Molina TJ, Casasnovas RO, Morschhauser F, Coiffier B
J Clin Oncol. 2018 Jan 25:JCO2017763961
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.
Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.
Cancer Med 2018 Feb 23. doi: 10.1002/cam4.1139
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L,Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G
ncet Oncol. 2018 Feb 20. pii: S1470-2045(18)30102-5
From genetics to the clinic: a translational perspective on follicular lymphoma
Huet S, Sujobert P, Salles G
Nat Rev Cancer. 2018 Feb 9. doi: 10.1038/nrc.2017.127
Bendamustine-Based conditioning prior to ASCT: Results of a French Multicenter Study of 474 Patients from LYSA Centers.
Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Bouabdallah K, Durot E, Damaj G.
Am J Hematol 2018 Feb 23. doi: 10.1002/ajh.25077
Prognostic value of baseline metabolic tumor volume in early stage Hodgkin’s lymphoma in the standard arm of H10 trial.
Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Bardet S, Castagnoli A, Brice P, Raemaekers J, Deau B, Fortpied C, Raveloarivahy T, Van Zele E, Chartier L, Vander Borght T, Federico M, Hutchings M, Ricardi U, Andre M, Meignan M
Blood 2018 Feb 1. pii: blood-2017-07-795476.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W.
Lancet 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2
Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
Cottereau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, Berriolo-Riedinger A, Menga M, Haioun C, Tilly H, Tarantino V, Federico M, Salles G, Trotman J, Meignan M
Blood 2018 Mar 20. pii: blood-2017-11-816298. doi: 10.1182/blood-2017-11-816298
RNA fusions involving CD28 are rare in peripheral T-Cell lymphomas and concentrate mainly in those derived from follicular helper T cells.
Vallois D, Dupuy A, Lemonnier F, Allen G, Missiaglia E, Fataccioli V, Ortonne N, Clavert A, Delarue R, Rousselet MC, Fabiani B, Llamas-Gutierrez F, Ogawa S, Thome M, Ko YH, Kataoka K, Gaulard P, de Leval L
Haematologica 2018 Mar 15. pii: haematol.2017.186767
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, Marolleau JP, Oberic L, Le Du K, Fornecker LM, Tournilhac O, Veillard AS, Chaillol I, Robin M, Tamburini J, Brice P
Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184.
Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
Cottereau AS, Buvat I, Kanoun S, Versari A, Casasnovas O, Chauvie S, Clerc J, Gallamini A, Meignan M.
Eur J Nucl Med Mol Imaging. 2018 Apr 12. doi: 10.1007/s00259-018-4005-4.
Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
Cottereau AS, El-Galaly TC, Becker S, Broussais F, Petersen LJ, Bonnet C, Prior JO, Tilly H, Hutchings M, Casasnovas O, Meignan M
J Nucl Med 2018 Apr;59(4):589-595. doi: 10.2967/jnumed.117.193946.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, da Silva MG, Fitoussi O, Belada D, Maisonneuve H, Intragumtomchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G
Blood 2018 Apr 17. pii: blood-2017-11-816405. doi: 10.1182/blood-2017-11-816405.
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS.
J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Delfau-Larue MH, van der Gucht A, Dupuis J, Jais JP, Nel I, Beldi-Ferchiou A, Hamdane S, Benmaad I, Laboure G, Verret B, Haioun C, Copie-Bergman C, Berriolo-Riedinger A, Robert P, Casasnovas RO, Itti E.
Blood Adv. 2018 Apr 10;2(7):807-816. doi: 10.1182/bloodadvances.2017015164.
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
Gisselbrecht C, Van Den Neste E.
Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15412.
Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Van den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Guesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F
Haematologica 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B.
Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes
Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Ekström Smedby K, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjosé S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay JD, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Wong Doo N, Giles GG, Southey MC, Milne RL, Offit K, Muskinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Boffetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF.
Cancer Res. 2018 May 7. pii: canres.2900.2017. doi: 10.1158/0008-5472.CAN-17-2900.
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.
Vo DN, Alexia C, Allende-Vega N, Morschhauser F, Houot R, Menard C, Tarte K, Cartron G, Villalba M.
Oncoimmunology. 2017 Dec 20;7(4):e1409322. doi: 10.1080/2162402X.2017.1409322. eCollection 2018.
2018_LYSA_Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from LYSA centers.
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H.
Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome For Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled On Randomized Clinical Trials.
Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B
Ann. Oncol. 2018 Jun 12. doi: 10.1093/annonc/mdy203.
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA)
Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15513
An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F, Salles G, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, Fabiani B, Ménard C, Tarte K, Cartron G, Houot R
Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499.
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorveaux V, Bouabdallah K, Amorin S, Garidi R, Voillat L, Joly B, Solal Celigny P, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB
Haematologica 2018 Aug 31. pii: haematol.2018.191429. doi: 10.3324/haematol.2018.191429
How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
Gisselbrecht C, Van Den Neste E
Br J Haematol 2018 Sep;182(5):633-643. doi: 10.1111/bjh.15412
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.
N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.
Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma
Al Tabaa Y, Tchernonog E, Faurie P, Cottereau AS, Monjanel H, Bonnet A, Le Gouill S, Gyan E, Ghesquieres H, Mariano-Goulart D, Cartron G
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1705-1709. doi: 10.1007/s00259-018-4020-5
Lysa 2020_LYSA_Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers
Hueso T, Gastinne T, Garciaz S, Tchernonog E, Delette C, Casasnovas RO, Durot E, Houot R, Tessoulin B, Tournilhac O, Malak S, Gyan E, Fornecker LM, Abraham J, Delapierre B, Peyrade F, Lemal R, Gressin R, Chantepie S, Borel C, Morello R, Bouabdallah K, Ibrahim A, Bouabdallah R, Le Gouill S, Damaj G
Bone Marrow Transplant. 2020 Jan 17. doi: 10.1038/s41409-020-0783-y En savoir plus
Lysa 2020_LYSA_A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features
Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot JM, Cuillière-Dartigues P, Suttle B, Karlin L, Le Gouill S, Picquenot JM, Dubois R, Tilly H, Herbaux C, Jardin F, Salles G, Ribrag V
Clin Cancer Res. 2020 Mar 2. doi: 10.1158/1078-0432.CCR-19-3741. En savoir plus
Lysa 2020_LYSA_Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR
Lancet Haematol. 2020 Feb;7(2):e112-e121. doi: 10.1016/S2352-3026(19)30210-8 En savoir plus
Lysa 2020_LYSA_Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
Mokrane FZ, Chen A, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Duléry R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Houot R, Dercle L https://www.ncbi.nlm.nih.gov/pubmed/32286191
Radiology. 2020 Apr 14:192056. doi: 10.1148/radiol.2020192056. En savoir plus
Locus suicide recombination actively occurs on the functionally rearranged IgH allele in B-cells from inflamed human lymphoid tissues.
Dalloul I, Boyer F, Dalloul Z, Pignarre A, Caron G, Fest T, Chatonnet F, Delaloy C, Durandy A, Jeannet R, Lereclus E, Boutouil H, Aldigier JC, Péron S, Le Noir S, Cook-Moreau J, Cogné
PLoS Genet. 2019 Jun 14 En savoir plus
Calym Mesangial Deposition Can Strongly Involve Innate-Like IgA Molecules Lacking Affinity Maturation
Wehbi B, Oblet C, Boyer F, Huard A, Druilhe A, Paraf F, Cogné E, Moreau J, El Makhour Y, Badran B, Van Egmond M, Cogné M, Aldigier JC.
Am Soc Nephrol. 2019 Jul En savoir plus
Calym An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence
Lee CH, Kang TH, Godon O, Watanabe M, Delidakis G, Gillis CM, Sterlin D, Hardy D, Cogné M, Macdonald LE, Murphy AJ, Tu N, Lee J, McDaniel JR, Makowski E, Tessier PM, Meyer AS, Bruhns P, Georgiou G.
Nat Commun. 2019 Nov 6 En savoir plus
Calym Pb Alpha-Radioimmunotherapy targeting CD38 in Multiple Myeloma: a preclinical study
Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, Garrier J, Cogne M, Durand-Panteix S.
Nucl Med. 2019 Dec 20. pii: jnumed.119.239491. doi: 10.2967/jnumed.119.239491. En savoir plus
Calym Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome.,”/
Bender S, Javaugue V, Saintamand A, Ayala MV, Alizadeh M, Filloux M, Pascal V, Gachard N, Lavergne D, Auroy F, Cogné M, Bridoux F, Sirac C, Jaccard A.","Blood. 2020 Apr 2. pii: blood.2019004197. doi: 10.1182/blood.2019004197
Blood. 2020 PMID: 32243509 DOI: 10.1182/blood.2019004197 En savoir plus
Calym Class-switched memory B cells remodel BCRs within secondary germinal centers.
McHeyzer-Williams LJ*, Milpied PJ*, Okitsu SL, McHeyzer-Williams MG. *co-first author
Nat Immunol. 2015 Mar;16(3):296-305. doi: 10.1038/ni.3095. En savoir plus
Calym Premalignant cell dynamics in indolent B-cell malignancies
Milpied P, Nadel B, Roulland S.
Curr Opin Hematol. 2015 Jul;22(4):388-96. doi: 10.1097/MOH.0000000000000159. En savoir plus
Calym High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice.
Crinier A, Milpied P, Escalière B, Piperoglou C, Galluso J, Balsamo A, Spinelli L, Cervera-Marzal I, Ebbo M, Girard-Madoux M, Jaeger S, Bollon E, Hamed S, Hardwigsen J, Ugolini S, Vély F, Narni-Mancinelli E, Vivier E.
. Immunity. 2018 Nov 20;49(5):971-986.e5. doi: 10.1016/j.immuni.2018.09.009. En savoir plus
Calym Human germinal center transcriptional programs are de-synchronized in B cell lymphoma.
Milpied P*, Cervera-Marzal I, Mollichella ML, Tesson B, Brisou G, Traverse-Glehen A, Salles G, Spinelli L, Nadel B*. *co-corresponding author
Nat Immunol. 2018 Sep;19(9):1013-1024. doi: 10.1038/s41590-018-0181-4. En savoir plus
Calym FB5P-seq: FACS-based 5-prime end single-cell RNA-seq for integrative analysis of transcriptome and antigen receptor repertoire in B and T cells.
Attaf A, Cervera-Marzal I, Dong C, Gil L, Renand A, Spinelli L, Milpied P.
Front Immunol. 2020 Mar 3;11:216. doi: 10.3389/fimmu.2020.00216. En savoir plus
Calym GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism.
Mondragón L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, Pons C, Chiche J, Jacquin M, Imbert V, Proïcs E, Boyer L, Doye A, Luciano F, Neels JG, Coutant F, Fabien N, Sormani L, Rubio-Patiño C, Bossowski JP, Muller F, Marchetti S, Villa E, Peyron JF, Gaulard P, Lemonnier F, Asnafi V, Genestier L, Benhida R, Fournié JJ, Passeron T, Ricci JE#, Verhoeyen E#.
Cancer Cell. 2019 Sep 16;36(3):268-287.e10. # co-senior and co-corresponding author
Calym Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes
Pizzolato G, Kaminski H, Tosolini M, Franchini DM, Pont F, Martins F, et al.
2019; 116:11906-11915. En savoir plus
Calym Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Rep
Franchini DM, Lanvin O, Tosolini M, Patras de Campaigno E, Cammas A, Péricart S, Scarlata CM, Lebras M, Rossi C, Ligat L, Pont F, Arimondo PB, Laurent C, Ayyoub M, Despas F, Lapeyre-Mestre M, Millevoi S, Fournié JJ.
2019 Jan 2;26(1):94-107.e7. En savoir plus
Calym EBV infection determines the immune hallmarks of plasmablastic lymphoma. Oncoimmunology
Gravelle P, Péricart S, Tosolini M, Fabiani B, Coppo P, Amara N, Traverse-Gléhen A, Van Acker N, Brousset P, Fournie JJ, Laurent C.
2018 Jul 30;7(10):e1486950. En savoir plus
Calym Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol
Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P.
2017 Jun 20;35(18):2008-2017. En savoir plus
Calym CELAC network. NKp46 is adiagnostic biomarker and may be a therapeutic target in gastrointestinal T-celllymphoproliferative diseases: a CELAC study.
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O.
Gut.2019;68:1396–405. En savoir plus
Calym Enhanced Renewal of Erythroid Progenitors inMyelodysplastic Anemia by Peripheral Serotonin
Sibon D, Coman T, Rossignol J, Lamarque M, Kosmider O, Bayard E, Fouquet G, Rignault R, Topçu S, Bonneau P, Bernex F, Dussiot M, Deroy K, Laurent L, Callebert J, Launay JM, Georgin-Lavialle S, Courtois G, Maroteaux L, Vaillancourt C, Fontenay M, Hermine O, Côté F.
Cell Rep.2019;26:3246-3256.e4. En savoir plus
Calym LYSA Group. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.N Engl J Med.
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O.
2017;377:1250-1260 En savoir plus
Calym European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M.
Lancet. 2016;388:565-75. En savoir plus
Calym G-CSFmobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease. Sci.Transl.
D'Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Santos e Sousa P, Bruneau J, Fouquet G, Zavala F, Alegria-Prévot O, Garfa-Traoré M, Suarez F, Trebeden-Nègre H, Mohty M, Bennett CL, Chakraverty R, Hermine O, Rubio MT.
Med. 2015;7:281ra42. En savoir plus
Calym GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors
Chiche J, Reverso-Meinietti J, Mouchotte A, Rubio-Patiño C, Mhaidly R, Villa E, Bossowski JP, Proics E, Grima-Reyes M, Paquet A, Fragaki K, Marchetti S, Briere J, Ambrosetti D, Michiels JF, Molina TJ, Copie-Bergman C, Lehmann-Che J, Peyrottes I, Peyrade F, de Kerviler E, Taillan B, Garnier G, Verhoeyen E, Paquis-Flucklinger V, Shintu L, Delwail V, Delpech-Debiais C, Delarue R, Bosly A, Petrella T, Brisou G, Nadel B, Barbry P, Mounier N, Thieblemont C, Ricci JE.
Cell Metab. 2019 Jun 4;29(6):1243-1257.e10.
Calym Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance.
Rubio-Patiño C, Bossowski JP, De Donatis GM, Mondragón L, Villa E, Aira LE, Chiche J, Mhaidly R, Lebeaupin C, Marchetti S, Voutetakis K, Chatziioannou A, Castelli FA, Lamourette P, Chu-Van E, Fenaille F, Avril T, Passeron T, Patterson JB, Verhoeyen E, Bailly-Maitre B, Chevet E, Ricci JE.
Cell Metab. 2018 Apr 3;27(4):828-842.e7.
Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells.
Villa E, Proïcs E, Rubio-Patiño C, Obba S, Zunino B, Bossowski JP, Rozier RM, Chiche J, Mondragón L, Riley JS, Marchetti S, Verhoeyen E, Tait SWG, Ricci JE.
Cell Rep. 2017 Sep 19;20(12):2846-2859.
GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α.
Chiche J, Pommier S, Beneteau M, Mondragón L, Meynet O, Zunino B, Mouchotte A, Verhoeyen E, Guyot M, Pagès G, Mounier N, Imbert V, Colosetti P, Goncalvès D, Marchetti S, Brière J, Carles M, Thieblemont C, Ricci JE.
Leukemia. 2015 May;29(5):1163-76
Calym Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, Amara N, Adélaïde J, Guille A, Schiano JM, Tesson B, Traverse-Glehen A, Chenard MP, Mescam L, Moreau A, Chassagne-Clement C, Somja J, Escudié F, André M, Martin N, Lacroix L, Lemonnier F, Hamy AS, Reyal F, Bannier M, Oberic L, Prade N, Frénois FX, Beldi-Ferchiou A, Delfau-Larue MH, Bouabdallah R, Birnbaum D, Brousset P, Xerri L, Gaulard P.
Blood. 2020 Jan 30;135(5):360-370. En savoir plus
Calym Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells. Cell Rep
Villa E, Proïcs E, Rubio-Patiño C, Obba S, Zunino B, Bossowski JP, Rozier RM, Chiche J, Mondragón L, Riley JS, Marchetti S, Verhoeyen E, Tait SWG, Ricci JE.
Cell Rep. 2017 Sep 19;20(12):2846-2859. En savoir plus
Calym 2019_GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism. Cancer Cell.
Mondragón L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, Pons C, Chiche J, Jacquin M, Imbert V, Proïcs E, Boyer L, Doye A, Luciano F, Neels JG, Coutant F, Fabien N, Sormani L, Rubio-Patiño C, Bossowski JP, Muller F, Marchetti S, Villa E, Peyron JF, Gaulard P, Lemonnier F, Asnafi V, Genestier L, Benhida R, Fournié JJ, Passeron T, Ricci JE#, Verhoeyen E#. # co-senior and co-corresponding author,
Cancer Cell. 2019 Sep 16;36(3):268-287.e10. En savoir plus
Calym 2019_GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. Cell Metab
Chiche J, Reverso-Meinietti J, Mouchotte A, Rubio-Patiño C, Mhaidly R, Villa E, Bossowski JP, Proics E, Grima-Reyes M, Paquet A, Fragaki K, Marchetti S, Briere J, Ambrosetti D, Michiels JF, Molina TJ, Copie-Bergman C, Lehmann-Che J, Peyrottes I, Peyrade F, de Kerviler E, Taillan B, Garnier G, Verhoeyen E, Paquis-Flucklinger V, Shintu L, Delwail V, Delpech-Debiais C, Delarue R, Bosly A, Petrella T, Brisou G, Nadel B, Barbry P, Mounier N, Thieblemont C, Ricci JE.
Cell Metab. 2019 Jun 4;29(6):1243-1257.e10. En savoir plus
Calym Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance. Cell Metab
Rubio-Patiño C, Bossowski JP, De Donatis GM, Mondragón L, Villa E, Aira LE, Chiche J, Mhaidly R, Lebeaupin C, Marchetti S, Voutetakis K, Chatziioannou A, Castelli FA, Lamourette P, Chu-Van E, Fenaille F, Avril T, Passeron T, Patterson JB, Verhoeyen E, Bailly-Maitre B, Chevet E, Ricci JE.
Cell Metab. 2018 Apr 3;27(4):828-842.e7. En savoir plus
Lysa 2020_LYSA_Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, Amara N, Adélaïde J, Guille A, Schiano JM, Tesson B, Traverse-Glehen A, Chenard MP, Mescam L, Moreau A, Chassagne-Clement C, Somja J, Escudié F, André M, Martin N, Lacroix L, Lemonnier F, Hamy AS, Reyal F, Bannier M, Oberic L, Prade N, Frénois FX, Beldi-Ferchiou A, Delfau-Larue MH, Bouabdallah R, Birnbaum D, Brousset P, Xerri L, Gaulard P
Blood. 2020 Jan 30;135(5):360-370. doi: 10.1182/blood.2019001904. En savoir plus
Calym 2019_Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner.
Bianco JN, Bergoglio V, Lin YL, Pillaire MJ, Schmitz AL, Gilhodes J, Lusque A, Mazières J, Lacroix-Triki M, Roumeliotis TI, Choudhary J, Moreaux J, Hoffmann JS, Tourrière H* and Pasero P*
Nat Commun, 10, 910. En savoir plus